Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus rating of “Hold” by the fourteen brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $17.56.
A number of research analysts have issued reports on the stock. BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Zacks Investment Research lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Bank of America lowered shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and reduced their target price for the company from $20.00 to $15.00 in a research note on Friday, January 5th.
In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total transaction of $927,000.00. Following the sale, the insider now directly owns 835,000 shares in the company, valued at approximately $12,900,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the sale, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The disclosure for this sale can be found here. Insiders have sold a total of 174,905 shares of company stock worth $2,666,359 over the last 90 days. 7.63% of the stock is owned by insiders.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded up $0.51 during trading on Friday, reaching $14.49. 1,275,045 shares of the company’s stock were exchanged, compared to its average volume of 1,889,750. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. The firm has a market cap of $2,077.10, a price-to-earnings ratio of -14.94 and a beta of 1.29. Ironwood Pharmaceuticals has a 52-week low of $12.89 and a 52-week high of $19.94.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.